SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation Leukemia (2015) 29, 253-255; doi:10.1038/leu.2014 Spliceosome gene mutations are among the 50-60 driver mutations underlying myelodysplastic syndromes (MDSs). 1 U2AF1 mutations for example have been reported to occur in up to 16% of primary myelofibrosis (PMF), and was found to be associated with anemia and thrombocytopenia in PMF. 2 We could show that spliceosome gene mutations are already present in early stages of PMF before fibrosis and cytopenia become manifest.
1
U2AF1 mutations for example have been reported to occur in up to 16% of primary myelofibrosis (PMF), and was found to be associated with anemia and thrombocytopenia in PMF. 2 We could show that spliceosome gene mutations are already present in early stages of PMF before fibrosis and cytopenia become manifest. 3 Recently, a negative association between mutations of calreticulin (CALR) and spliceosome genes has been described. 4 CALR is a Ca 2+ -binding protein, which was found in 2013 to be mutated in JAK2-or MPL-unmutated PMF and essential thrombocythemia. 5, 6 Mutations were mutually exclusive of JAK2 or MPL mutations. JAK2-mutated and triple-negative patients were shown to have significantly shorter survival periods in comparison to those with somatic frameshift mutations in the CALR gene. 4, 5 Tefferi et al. 4 described significantly lower frequency of spliceosome mutations in CALR-mutated cases and attributed the lower incidence of anemia to the lower frequency of U2AF1 mutations.
Up to now allogeneic hematopoietic stem cell transplantation (AHSCT) represents the only curative treatment modus for patients with PMF. 7 Selection of patients suitable for this kind of treatment is performed according to prognostic scoring and tolerable risks of individual patients. Data of Heuser et al. 8 suggest a better overall survival for CALR-mutated PMF patients after AHSCT.
In this study, we analyzed 69 patients with PMF grades of fibrosis 2-3 (Table 1 ) who have undergone allogenic stem cell transplantation for JAK2, MPL, CALR and spliceosome gene mutations (SRSF2, U2AF1 and SF3B1) using bone marrow trephines and pyrosequencing as described.
9
CALR was rarely combined with splice factor gene mutations (10.5% of all CALR-mutated cases; negative correlation, P = 0.0418) and these combinations were restricted to SF3B1. Combined mutations with U2AF1 and SRSF2 could not be found at all. The frequency of accompanying splice factor gene mutations in CALR-mutated patients was significantly lower than that in patients without a CALR mutation (21/50, 42%; P = 0.04) or in those with a JAK2 mutation (18/41, 44%; P = 0.04). U2AF1 was the most frequent splice factor gene mutation associated with JAK
V617F
. In PMF, splice factor gene mutations were associated significantly more often with a JAK2 mutation than with a CALR mutation (Po0.00005; Fisher's exact tests).
In our cohort 7 patients (10%) revealed neither JAK2 nor MPL or CALR mutation. In the 'triple-negative' subgroup of PMF, exclusively mutations of SRSF2 occurred (n=2), but no alterations of U2AF1 and SF3B1 could be observed ( Table 1) .
Because of the low number of MPL-mutated cases in this series additional samples of PMF with bone marrow fibrosis grade 2-3 and known MPL mutation (n = 20, all JAK2 exon 14 wild type) were investigated for combination with splice factor gene mutations.
Among the 20 MPL-mutated cases 10 samples exhibited splice factor gene mutations (50%). Three samples revealed mutation of U2AF1 (15%), six of SRSF2 (30%) and one of SF3B1 (5%), respectively. Consequently, MPL-mutated PMF cases appear to carry splice factor gene mutations with a similar frequency as JAK2-mutated cases. CALR-mutated cases behave different from JAK2-and MPL-mutated cases in that splice factor gene mutations occur significantly rarer (P o 0.005 for MPL) and only combinations with SF3B1 could be found.
After a median follow-up of 18 months four patients suffered molecular and histopathological relapse. Interestingly, the recurrent disease was different from the primary MPN and differences with regard to histopathology as well as to molecular aberrations could be observed. In two patients the bone marrow displayed reduced myelofibrosis ( oMF2) but cytopenia was still evident (Patient 3 and 4 in Table 2 ). JAK2 mutation was no longer detectable in these cases but splice factor gene mutations persisted and as shown for SRSF2 to a similar allelic burden as in the bone marrow before AHSCT. Bone marrow biopsy in one case (patient 3) still revealed atypical megakaryocytes and myelofibrosis (MF1), consistent with relapse of PMF but with reduction of fibrosis ( Table 2 ). In another case with persisting U2AF1 mutation after AHSCT histology showed a different picture more reminiscent of MDS with excess of blasts, and megakaryocytes did not show the atypia anymore characteristic for PMF (patient 4, Table 2 ). In patient No 1 JAK2 mutation was still detectable, but with a reduced allelic burden (15%) compared with the primary biopsy (80%), whereas SRSF2 mutation remained on an identical level of 50% (Table 2 ). In this case myelofibrosis was also diminished 1 year after AHSCT (MF grade 3 to MF grade 1) but increased again to MF grade 2 after 4 years. In addition, there was one case with persisting JAK2 mutation and loss of splice factor gene mutations (U2AF1) after AHSCT (patient 2).
Our results show that PMF with high-risk scores eligible for AHSCT represents a molecularly heterogeneous disease despite uniform histopathology of bone marrow with atypical megakaryocytic proliferation and evident myelofibrosis. Cytopenia which is used for risk stratification and which is the dominant cause to treat patients with AHSCT appears to be associated in a considerable proportion of PMF cases with splice factor gene mutations. In these cases fibrotic obliteration of bone marrow spaces seems not to be the only cause of cytopenia. Splice factor gene mutations are significantly more frequently combined with JAK2 and MPL mutations than with CALR mutation. Furthermore, different hematopoietic clones proliferate in PMF giving rise to a molecular mosaic. After AHSCT of PMF relapses may uncover the underlying clonal mosaic and different diseases may emerge. Despite reduction of myelofibrosis and eradication of the JAK2 V617F clone cytopenia may persist. The molecular mosaic in myeloproliferative neoplasms has been demonstrated to be the result of both independent clones Accepted article preview online 18 September 2014; advance online publication, 10 October 2014 proliferating in parallel as well as clonal evolution with stepwise acquisition of different mutations by a single neoplastic clone. 10 Molecular monitoring of patients having undergone AHSCT for PMF should not be restricted to JAK2, MPL or CALR, but all mutations present in the primary fibrotic neoplastic myeloproliferation should be included to interpret abnormal blood values after AHSCT. The apparently better prognosis of CALR-mutated PMF.
4,5 including cases treated with AHSCT 8 may at least in part be attributable to a less likely association with splice factor gene mutations. Abbreviations: +AHCST, after allogeneic hematopoietic stem cell transplantation; MF 0-3, grade of myelofibrosis; P, patient; PMF, primary myelofibrosis; WT, wild type. Protein kinase N family genes encode AGC-type serine-threonine kinases (PKN1, PKN2 and PKN3) that interact with Rho family proteins to regulate cytoskeletal organization and gene expression. [1] [2] [3] Whereas PKN1 and PKN2 are ubiquitously expressed, PKN3 expression is low in most normal human tissues but high in some malignancies.
3 PKN3 catalytic activity is regulated by RhoC and by the PI3-kinase (PI3K) signaling pathway. 4, 5 PKN3 inactivation inhibits growth of PI3K-driven prostate and breast cancer xenografts. 4, 5 Its role in hematopoietic malignancies has not yet been described. Since the PI3K pathway is hyper-activated in many types of leukemia, [6] [7] [8] PKN3 may be a useful target for treating leukemia patients.
We analyzed PKN1, PKN2 and PKN3 expression in human T-cell acute lymphoblastic leukemia (T-ALL), a subtype that is often driven by hyper-active PI3K signaling. 8, 9 We analyzed 7 control bone marrow samples and 117 primary T-ALL samples from a previously published microarray data set.
10 PKN1 and PKN2 were expressed at similar levels in control bone marrow and T-ALL specimens, but PKN3 was expressed at significantly higher levels in human T-ALL relative to normal bone marrow (Figures 1a-c ), granulocyte-monocyte progenitors (GMPs) and thymocytes relative to unfractionated bone marrow. Pkn3 was expressed in all cell populations, and it was most highly expressed in immature HSCs, RPs and GMPs (Figure 1d ). These data raise the question of whether PKN3 regulates normal hematopoiesis and T-cell leukemogenesis.
We used genetically engineered mice to test whether Pkn3 regulates normal hematopoiesis and T-cell leukemogenesis in vivo. A conditional Pkn3 allele (Pkn3 fl ) was generated by flanking exons 2-6 with LoxP sites (Supplementary Figure S1A) . Cre-mediated deletion of exons 2-6 caused a frame shift after codon 5 and a premature translational stop signal at codon 20. Germ line-deleted Pkn3 −/− mice did not express transcripts from exons 2-6 or the PKN3 protein (Supplementary Figures S1B and C) , consistent with our expectation that this deletion yields a null allele. Pkn3 −/− mice were born in expected Mendelian ratios. They were viable, fertile and healthy, so Pkn3 is not essential for normal development or homeostasis.
To test whether Pkn3 regulates HSC function and hematopoiesis we generated Pkn3 fl/fl ; Mx1-Cre mice and initiated poly-Inosine: poly-Cytosine (pIpC) treatments 6 weeks after birth to induce Cre expression (10 μg pIpC/dose for three doses). We genotyped HSCderived colonies and confirmed that this pIpC dose was sufficient to delete both Pkn3 alleles in all HSCs (data not shown). At 8 weeks after pIpC treatment Pkn3 fl/fl ; Mx1-Cre mice had normal peripheral blood counts relative to littermate (Cre-negative) controls (Figures 1e-g ). Control and Pkn3-deleted mice had similar numbers of HSCs in their bone marrow (Figure 1h ). To assess the effects of embryonic Pkn3 deletion, we generated Pkn3 ; Vav-Cre marrow (Figure 1l ). Based on these data, Pkn3 does not appear to be essential for normal hematopoiesis.
We next tested whether Pkn3 contributes to changes in HSC function and leukemogenesis that occur following Pten deletion.
11,12 Pten encodes a lipid phosphatase that negatively regulates the PI3K pathway. 13 Pten deletion impairs HSC function, and Pten-deleted mice develop myeloproliferative neoplasms (MPN) and T-ALL.
11,14 These phenotypes can be completely attenuated by simultaneously deleting Rictor to inactivate mTORC2 and its substrate, AKT.
14 Since the PI3K pathway activates PKN3 in some cancers, 4 we tested whether Pkn3 deletion can prevent HSC mobilization, MPNs, impaired HSC function and T-ALL in Pten-deleted mice.
We first characterized Pkn3 expression in control and Ptendeleted hematopoietic cells. Pten deletion caused a significant reduction in Pkn3 expression in HSCs and in MPN (~50 and 75%, respectively; Figure 2a ). In contrast, Pten deletion did not significantly alter Pkn3 expression in thymocytes or T-ALL cells. Thus, the effects of PI3K pathway activation on Pkn3 expression are cell-type specific. This raises the question of whether genetic interactions between Pten and Pkn3 are also cell-type specific.
To test whether Pkn3 deletion rescues the HSC mobilization and MPN phenotypes, we generated Pten ; Mx1-Cre (Pten Δ/Δ ) littermate mice. We deleted Pten and Pkn3 6 weeks after birth and analyzed spleen weights and HSC numbers 2 weeks later. We found that both Pten Δ/Δ and Pten/Pkn3 Δ/Δ mice had enlarged spleens, and spleen HSC numbers were similarly increased in both Pten 
